Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q4 FY21 results · Jan–Mar 2021

Jubilant Pharmova reported revenue from operations of ₹1,579.78 crore (down 33.9% from Q4 FY20) and net profit of ₹213.65 crore (down 18.0% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY21	Q4 FY20	YoY	Q3 FY21	QoQ
Revenue from operations	1,579.78	2,391.41	−33.9%	1,771.34	−10.8%
Other income	6.69	19.44	−65.6%	3.59	+86.4%
Total income	1,586.47	2,410.85	−34.2%	1,774.93	−10.6%
Profit before share of associates & JVs and tax	241.39	355.95	−32.2%	343.15	−29.7%
Share of profit/(loss) of associates & JVs	14.35	0.00		(3.10)
Net profit for the period	213.65	260.49	−18.0%	309.83	−31.0%
Attributable to shareholders of the company	213.90	260.49	−17.9%	309.93	−31.0%
EPS, basic (₹)	13.43	16.35	−17.9%	19.46	−31.0%
Net margin (%)	13.5	10.9		17.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY21	Q4 FY20	YoY	Q3 FY21	QoQ
Revenue from operations	365.86	791.36	−53.8%	828.94	−55.9%
Other income	13.80	82.69	−83.3%	12.21	+13.0%
Total income	379.66	874.05	−56.6%	841.15	−54.9%
Profit before tax	45.87	110.36	−58.4%	80.99	−43.4%
Net profit for the period	35.16	111.18	−68.4%	64.65	−45.6%
EPS, basic (₹)	2.21	6.98	−68.3%	4.06	−45.6%
Net margin (%)	9.6	14.0		7.8

Consolidated

Filed with BSE: 05 Jun 2021, 17:15 IST
Board meeting: 04 Jun 2021
Period: 01 Jan 2021 to 31 Mar 2021
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 05 Jun 2021, 17:15 IST
Board meeting: 04 Jun 2021
Period: 01 Jan 2021 to 31 Mar 2021
Review status: Audited
Source: XBRL filing on BSE